Monitor for any data readouts or partnership announcements from Valneva's presentations at the World Vaccine Congress, which could provide early signals of commercial traction or regulatory progress for IXCHIQ.
Price Chart
Executive Summary
Valneva announced its participation in the 26th World Vaccine Congress in Washington, DC, where it will present updates on its chikungunya vaccine IXCHIQ, including real-world evidence from a pilot vaccination campaign in Brazil involving over 12,000 individuals. The company will also engage in discussions on mosquito-borne diseases and meet with current and potential partners.
Key Facts
- Valneva will present chikungunya vaccine IXCHIQ Phase IV and real-world evidence data at the World Vaccine Congress on April 1, 2026.
- Over 12,000 people have been vaccinated in a pilot campaign in Brazil with IXCHIQ, conducted in partnership with Instituto Butantan.
- The data presented will support post-marketing commitments and evaluate the real-world effectiveness and safety of IXCHIQ.
- Valneva executives will participate in a panel discussion on mosquito-borne vaccines and outbreak response.
- The company will maintain a presence at booth #538 to meet with partners.
Financial Impact
Not specified
Risk Factors
- The filing contains forward-looking statements subject to risks including regulatory delays, manufacturing challenges, and uncertain clinical outcomes.
- Real-world data may reveal safety or efficacy concerns not seen in clinical trials, potentially impacting commercial adoption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-021321 |
| Document: a6-kcoverpagetemplate.htm | 0001628280-26-021321 |
| Document: 0001628280-26-021321-index-headers.html | 0001628280-26-021321 |
| Document: 0001628280-26-021321-index.html | 0001628280-26-021321 |
| Document: 0001628280-26-021321.txt | 0001628280-26-021321 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 17, 2026 15w ago | EFFECT | $5.35 $6.66 | ▲ +24.49% | ▲ +21.34% | $5.74 (+7.29%) |
Jun 5, 2026 17w ago | 6-K | $5.48 $6.30 | ▲ +14.96% | ▲ +10.96% | $5.74 (+4.74%) |
Jun 1, 2026 17w ago | 6-K | $5.95 $6.78 | ▲ +13.95% | ▲ +12.72% | $5.74 (−3.53%) |
May 5, 2026 21w ago | 6-K | $5.29 $5.09 | ▼ −3.85% | ▼ −6.59% | $5.74 (+8.51%) |
Mar 26, 2026 27w ago | 6-K | $6.32 $5.35 | ▼ −15.35% | ▼ −29.30% | $5.74 (−9.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access